Global prevalence of autism and other pervasive developmental disorders
We provide a systematic review of epidemiological surveys of autistic disorder and
pervasive developmental disorders (PDDs) worldwide. A secondary aim was to consider the …
pervasive developmental disorders (PDDs) worldwide. A secondary aim was to consider the …
Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease …
Background In 2010, overweight and obesity were estimated to cause 3· 4 million deaths, 3·
9% of years of life lost, and 3· 8% of disability-adjusted life-years (DALYs) worldwide. The …
9% of years of life lost, and 3· 8% of disability-adjusted life-years (DALYs) worldwide. The …
Functional profiling of the Saccharomyces cerevisiae genome
…, JN Strathern, G Valle, M Voet, G Volckaert, C Wang… - nature, 2002 - nature.com
Determining the effect of gene deletion is a fundamental approach to understanding gene
function. Conventional genetic screens exhibit biases, and genes contributing to a …
function. Conventional genetic screens exhibit biases, and genes contributing to a …
The belle detector
A Abashian, K Gotow, N Morgan, L Piilonen… - Nuclear Instruments and …, 2002 - Elsevier
The Belle detector was designed and constructed to carry out quantitative studies of rare B-
meson decay modes with very small branching fractions using an asymmetric e+ e− collider …
meson decay modes with very small branching fractions using an asymmetric e+ e− collider …
Airborne transmission of respiratory viruses
BACKGROUND Exposure to droplets produced in the coughs and sneezes of infected
individuals or contact with droplet-contaminated surfaces (fomites) have been widely …
individuals or contact with droplet-contaminated surfaces (fomites) have been widely …
[HTML][HTML] A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19
…, PW Horby, D Zhang, C Wang - New England journal …, 2020 - Mass Medical Soc
Background No therapeutics have yet been proven effective for the treatment of severe
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open …
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open …
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
…, G Fan, J Xu, G Wang, Y Wang, J Zhong, C Wang… - The Lancet, 2021 - thelancet.com
Background The long-term health consequences of COVID-19 remain largely unclear. The
aim of this study was to describe the long-term health consequences of patients with COVID …
aim of this study was to describe the long-term health consequences of patients with COVID …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
…, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
[HTML][HTML] Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general …
C Wang, R Pan, X Wan, Y Tan, L Xu, CS Ho… - International journal of …, 2020 - mdpi.com
Background: The 2019 coronavirus disease (COVID-19) epidemic is a public health
emergency of international concern and poses a challenge to psychological resilience …
emergency of international concern and poses a challenge to psychological resilience …
[HTML][HTML] Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
…, SJ Swanson, K Kerr, C Wang… - … England Journal of …, 2022 - Mass Medical Soc
Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …